BAYLOR COLLEGE OF MEDICINE
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1900-10-30
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.bcm.edu
Clinical Trials
728
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (607 trials with phase data)• Click on a phase to view related trials
Assessing the Efficacy of Indocyanine Green for Ureter Identification During Robot-Assisted Surgery in Advanced-Stage Endometriosis
- Conditions
- Indocyanine Green (ICG)Robotic Surgical ProcedureDeep Infiltrating Endometriosis (DIE)Endometriosis PelvicEndometriosis (Diagnosis)Endometriosis of the Cul-de-sacUreteral Stent PlacementUreteral InjuryEndometriosis Ovaries
- Interventions
- Drug: Indocyanine Green (ICG)-Assisted Ureteral IdentificationProcedure: Standard Ureteral Identification without ICG
- First Posted Date
- 2025-08-28
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT07144904
- Locations
- 🇺🇸
Texas Childrens Hospital Pavilion for Women, Houston, Texas, United States
TETRAVI Expanded Access Program
- Conditions
- Cytomegalovirus InfectionsViral Infections Post-TransplantPost-Allogeneic Stem Cell Transplant ComplicationsEpstein-Barr Virus InfectionJC Virus InfectionAdenovirus InfectionBK Virus Infection
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Baylor College of Medicine
- Registration Number
- NCT07104591
Genetic Study to Determine the Cause of Birth Defects in Newborns in Texas
- Conditions
- Rare Diseases
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 410
- Registration Number
- NCT07102966
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Neonatal Neurodevelopmental Outcomes
- Conditions
- Food InsecurityDepressionAnxietyStress
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 200
- Registration Number
- NCT07101757
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
Self-Administered Interactive Exercise Program (Tele-Exergame)
- Conditions
- Mild Cognitive Impairment (MCI)Mild Alzheimer DiseaseMemory Deficits
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT07072962
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 146
- Next
News
Greenwich LifeSciences' GLSI-100 Receives FDA Fast Track Designation for HER2-Positive Breast Cancer Prevention
Greenwich LifeSciences announced that the FDA has granted Fast Track designation for GLSI-100, an immunotherapy designed to prevent breast cancer recurrences in HLA-A*02 patients with HER2-positive breast cancer.
DAPA ACT HF-TIMI 68 Trial Shows Promise for In-Hospital SGLT2 Inhibitor Initiation Despite Missing Primary Endpoint
The DAPA ACT HF-TIMI 68 trial failed to show significant improvement in cardiovascular death or worsening heart failure when starting dapagliflozin during acute heart failure hospitalization, with 10.9% of treated patients versus 12.7% of placebo patients experiencing events at 60 days.
Oral Testosterone Undecanoate Shows Superior Sexual Function Improvements in Phase 3 Trial
Oral testosterone undecanoate (Jatenzo) significantly improved serum testosterone levels, with 92% of men achieving levels of 450 ng/dL or higher by day 105 in the inTUne phase 3 trial.
Dual Clinical Trials Advance Mesothelioma Treatment with Novel Immunotherapy Combinations
Baylor College of Medicine and Duke University are conducting a clinical trial combining chemotherapy and immunotherapy before and after surgery for resectable mesothelioma patients, enrolling 52 participants.
First Commercial Brain Gene Therapy Treatments Delivered in US Using ClearPoint Neuro's SmartFlow Cannula
The first commercial gene therapy treatments ever delivered directly to the brain in the United States have been successfully performed using ClearPoint Neuro's SmartFlow Neuro Cannula to administer KEBILIDI for AADC deficiency.
Psilocybin Shows Anti-Aging Properties in Preclinical Study, Extending Cellular Lifespan by 50%
Emory University researchers demonstrated that psilocin, the active metabolite of psilocybin, extended human skin and lung cell lifespans by more than 50% in laboratory studies.
Breakthrough mRNA Vaccine Shows Promise Against Deadly Elephant Virus in First Real-World Test
Two young Asian elephants at Cincinnati Zoo successfully overcame Elephant Endotheliotropic Herpesvirus (EEHV) infection after receiving an experimental mRNA vaccine developed by Houston Zoo and Baylor College of Medicine.
ERA 2025 to Feature Pivotal Nephrology Trials Including CONFIDENCE, ACHIEVE, and VISIONARY Studies
The 62nd European Renal Association Congress in Vienna will present seven late-breaking clinical trials addressing chronic kidney disease, dialysis patients, and glomerular disease developments.
U.S. Measles Outbreak Intensifies: 600+ Cases Reported as HHS Secretary's Stance on Vaccines Draws Criticism
A severe measles outbreak has spread to 21 states with over 600 confirmed cases in 2025, primarily affecting unvaccinated individuals, with experts suspecting significant underreporting of actual case numbers.
Election-Related Stress Reaches Critical Levels Among Americans, APA Survey Reveals
A new American Psychological Association poll reveals 77% of Americans report stress about the nation's future, with 69% specifically worried about the upcoming presidential election.